First Allied Advisory Services’s Karyopharm Therapeutics KPTI Stock Holding History

First Allied Advisory Services’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,390	Closed	-$203K	–	1139
2016 Q3	$203K	Buy	+1,390	New	+$167K	0.01%	936

Other funds holding KPTI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Allied Advisory Services's KPTI Position: Q4 2016 in Review

First Allied Advisory Services sold out of Karyopharm Therapeutics (KPTI) in Q4 2016, closing a stake of 1,390 shares — an estimated $203K sold.

First Allied Advisory Services first reported a position in KPTI in Q3 2016 and held it in 1 quarter. The position peaked at $203K in Q3 2016. 86 funds tracked by Wall St. Rank hold KPTI as of Q4 2016.

First Allied Advisory Services reported no remaining Karyopharm Therapeutics position as of Q4 2016 after selling out during the quarter.
First Allied Advisory Services sold 1,390 Karyopharm Therapeutics shares in Q4 2016, an estimated $203K.
First Allied Advisory Services first reported a position in Karyopharm Therapeutics in Q3 2016 and held it in 1 quarter.
First Allied Advisory Services's Karyopharm Therapeutics position peaked at $203K in Q3 2016.
86 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2016.

Based on First Allied Advisory Services's 13F filing for Q4 2016, filed 13 Feb 2017.